by Nicole Kuchinsky | Dec 5, 2017
One of my personal highlights from this year’s Till and McCulloch Meetings was attending the “Science for Citizens” panel (reported on in a previous post). Experts including Timothy Caulfield, patient advocate William Brock, and National Post writer Tom...
by Sowmya Viswanathan | Nov 30, 2017
The recent FDA approvals of Kymriah™ for the treatment of children and young adults with B-cell Acute Lymphoblastic Leukemia, and Yescarta™ to treat adults with certain types of non-Hodgkin lymphoma, and the unanimous endorsement by an FDA advisory committee of a gene...
by Samantha Yammine | Nov 23, 2017
With the extensive exploitation of regenerative medicine through the marketing and selling of unapproved stem cell “therapies” online, it was refreshing to hear an update about clinical trials for a legitimate stem cell therapy at the Till & McCulloch Meetings...
by Hamideh Emrani | Nov 16, 2017
Imagine your hands lose their control and, all of a sudden, the glass of water you just took from the fridge slips and shatters on the ground. What could it be? “It is probably carpel tunnel syndrome,” says your family doctor. But you experience more problematic...
by Hamideh Emrani | Nov 16, 2017
This year, Dr. Harold Atkins was honored with the Till & McCulloch Award. He and Dr. Mark Freedman led a clinical trial that used stem cells to reset the immune system as a treatment strategy for Multiple Sclerosis (MS) and a few other neurodegenerative...
by Hamideh Emrani | Nov 9, 2017
Another interesting talk, on the first morning of the Canadian Till & McCulloch Meetings, was from Dr. Bruce Verchere who spoke about possible routes to prevent graft rejection in the case of human β-cell and islet cell transplants for diabetes through...
Comments